World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment [a]

HIV

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Aid to diagnosis	Rapid diagnostic tests [c]	Serum/plasma, capillary whole blood, oral fluid, urine
	Enzyme immunoassays	Serum/plasma
	Nucleic acid tests (qualitative)	Whole blood, Dried blood spot
Monitoring	Flow cytometer for enumeration of lymphocyte subset including CD4+ T cells, or a technology that can be used at or near the patient (quantitative or semi-quantitative)	Whole blood
	Nucleic acid tests for measuring viral load (quantitative or semi-quantitative)	Plasma, Dried blood spot, Plasma separation card

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[c] Including rapid diagnostic tests intended for self testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Hepatitis C virus

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Aid to diagnosis	Rapid diagnostic tests	Serum/plasma
	Enzyme immunoassays	Serum/plasma
Aid to diagnosis and monitoring	Nucleic acid tests (quantitative or qualitative)	Plasma, Dried blood spot

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Hepatitis B virus

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Aid to diagnosis and monitoring	Rapid diagnostic tests	Serum/plasma
	Enzyme immunoassays	Serum/plasma
Monitoring	Quantitative nucleic acid tests	Plasma

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Malaria parasites

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Aid to diagnosis and monitoring	Rapid diagnostic tests	Serum/plasma

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Human papilloma virus

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Screening	Nucleic acid tests (DNA or mRNA)	Cervical swab

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Glucose-6-phosphate dehydrogenase (G6PD) enzyme

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Enzyme deficiency detection	Technologies/formats to be used at or near the patient (quantitative or semi-quantitative or qualitative)	Whole blood

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Toxigenic Vibrio cholerae

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Surveillance	Rapid diagnostic tests	Stool

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Treponema pallidum (Syphilis)

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Screening and aid to diagnosis	Rapid diagnostic tests [c]	Serum/plasma

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

Mycobacterium tuberculosis complex and resistance to first and/or second line anti-tuberculosis drugs

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Aid to diagnosis	Qualitative nucleic acid tests	Sputum

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.
[c] Including rapid diagnostic tests intended for self-testing

World Health Organization

Table 1: Products currently eligible for WHO's performance evaluation as a prerequisite to apply for WHO's prequalification assessment[a]

SARS-CoV-2

Function of the test	Technology	Performance evaluation protocols available for the following specimen types[b]
Aid to diagnosis	Rapid diagnostic tests	Nasopharyngeal swabs, nasal swabs
	Qualitative nucleic acid tests	Analytical evaluation only, not dependent on specimen type

[a] For multiplex tests, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[b] If no claimed specimen types are included in the table above, the manufacturer is requested to contact WHO in advance of submitting an EOI.

[c] Including rapid diagnostic tests intended for self-testing